Literature DB >> 30693820

Intestinal microbiota predicts lung cancer patients at risk of immune-related diarrhea.

Tian Liu1, Qi Xiong1, Lingling Li1, Yi Hu1.   

Abstract

AIM: Previous studies showed that some patients after the treatment of anti-programmed cell death protein-1 (anti-PD-1) antibodies experienced immune-related diarrhea. In this study, we aim to explore the association between intestinal microbiota and immune-related diarrhea.
METHODS: We obtained the fecal samples of 26 advanced lung cancer patients before the first dose of anti-PD-1 antibodies.
RESULTS: Eight of 26 patients experienced diarrhea after the treatment of anti-PD-1 antibodies. At the phylum level, our study demonstrated that Bacteroidetes were higher in diarrhea-free (D-F) patients, while Firmicutes were lower. Bacteroides and Parabacteroides belonging to Bacteroidetes phylum and Phascolarctobacterium of Firmicutes phylum were more abundant in D-F patients. Whereas, Veillonella of Proteobacteria phylum was lower in D-F patients.
CONCLUSION: Our study highlights that intestinal microbiota variation is correlated with the subsequent development of immune-related diarrhea.

Entities:  

Keywords:  16S rRNA; PD-1; anti-PD-1 antibodies; immune-related diarrhea; intestinal microbiota

Mesh:

Substances:

Year:  2019        PMID: 30693820     DOI: 10.2217/imt-2018-0144

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  14 in total

Review 1.  Gut Microbiota: the Emerging Link to Lung Homeostasis and Disease.

Authors:  An Zhou; Yuanyuan Lei; Li Tang; Shiping Hu; Min Yang; Lingyi Wu; Shiming Yang; Bo Tang
Journal:  J Bacteriol       Date:  2021-01-25       Impact factor: 3.490

2.  Does the gut microbiota play a key role in PD-1/PD-L1 blockade therapy?

Authors:  Satoshi Watanabe; Toshiaki Kikuchi
Journal:  Transl Lung Cancer Res       Date:  2020-06

Review 3.  Influence of immunomodulatory drugs on the gut microbiota.

Authors:  Inessa Cohen; William E Ruff; Erin E Longbrake
Journal:  Transl Res       Date:  2021-01-27       Impact factor: 10.171

4.  A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors.

Authors:  Fyza Y Shaikh; James R White; Joell J Gills; Taiki Hakozaki; Corentin Richard; Bertrand Routy; Yusuke Okuma; Mykhaylo Usyk; Abhishek Pandey; Jeffrey S Weber; Jiyoung Ahn; Evan J Lipson; Jarushka Naidoo; Drew M Pardoll; Cynthia L Sears
Journal:  Clin Cancer Res       Date:  2021-02-16       Impact factor: 13.801

Review 5.  Gut microbiota: impacts on gastrointestinal cancer immunotherapy.

Authors:  Harry Cheuk Hay Lau; Joseph Jao-Yiu Sung; Jun Yu
Journal:  Gut Microbes       Date:  2021 Jan-Dec

6.  Relating Gut Microbiome and Its Modulating Factors to Immunotherapy in Solid Tumors: A Systematic Review.

Authors:  Chengliang Huang; Meizhang Li; Ben Liu; Huanbo Zhu; Qun Dai; Xianming Fan; Kathan Mehta; Chao Huang; Prakash Neupane; Fen Wang; Weijing Sun; Shahid Umar; Cuncong Zhong; Jun Zhang
Journal:  Front Oncol       Date:  2021-03-18       Impact factor: 6.244

Review 7.  Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis.

Authors:  Harm Westdorp; Mark W D Sweep; Mark A J Gorris; Frank Hoentjen; Marye J Boers-Sonderen; Rachel S van der Post; Michel M van den Heuvel; Berber Piet; Annemarie Boleij; Haiko J Bloemendal; I Jolanda M de Vries
Journal:  Front Immunol       Date:  2021-10-29       Impact factor: 7.561

Review 8.  The Cross-Talk Between Gut Microbiota and Lungs in Common Lung Diseases.

Authors:  Dapeng Zhang; Sha Li; Ning Wang; Hor-Yue Tan; Zhimin Zhang; Yibin Feng
Journal:  Front Microbiol       Date:  2020-02-25       Impact factor: 5.640

Review 9.  [Mechanism and Research Progress of Microbiome in the Development of Lung Cancer].

Authors:  Guohui Liu; Anxin Gu; Mingyan E
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-08-21

Review 10.  Diet, Microbiome, and Cancer Immunotherapy-A Comprehensive Review.

Authors:  Michał Szczyrek; Paulina Bitkowska; Patryk Chunowski; Paulina Czuchryta; Paweł Krawczyk; Janusz Milanowski
Journal:  Nutrients       Date:  2021-06-28       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.